002720 — Kukje Pharma Co Income Statement
0.000.00%
Last trade - 00:00- KR₩104bn
- KR₩124bn
- KR₩175bn
Annual income statement for Kukje Pharma Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 119,746 | 126,583 | 135,373 | 156,463 | 175,496 |
| Cost of Revenue | |||||
| Gross Profit | 54,470 | 63,254 | 67,225 | 82,495 | 93,645 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 121,425 | 121,787 | 139,229 | 149,787 | 169,327 |
| Operating Profit | -1,679 | 4,797 | -3,856 | 6,676 | 6,169 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1,110 | 4,745 | -6,681 | 6,609 | 6,443 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1,556 | 3,543 | -8,415 | 5,206 | 5,705 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -1,559 | 3,557 | -8,415 | 5,205 | 5,698 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1,559 | 3,557 | -8,415 | 5,205 | 5,698 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -76.6 | 193 | -365 | 253 | 280 |
| Dividends per Share |